FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2254608986> ?p ?o ?g. }

• W2254608986 endingPage "583" @default.
• W2254608986 startingPage "579" @default.
• W2254608986 abstract "The aim of this phase II trial was to assess the efficacy of fludarabine monophosphate in untreated and pretreated mantle-cell lymphomas (MCL).Fifteen patients with MCL were included in the study. In two cases, fludarabine was the first-line therapy, the second in four cases, the third in five cases, and the fourth in four cases. The diagnosis of MCL was based on the criteria of the European Lymphoma Task Force (ELTF), with morphologic, immunologic, and cytogenetic data. Patients were treated with intravenous fludarabine 25 mg/m2/d for 5 days every 4 weeks.Toxicity of fludarabine was mild: World Health Organization (WHO) grade 3 and 4 granulocytopenia occurred in 15 of 56 assessable cycles (cy) (27%), there was no grade 3 or 4 thrombocytopenia, one grade 3 bacterial lung infection, and no treatment-related death. There were five partial responses (33%) but no complete response. The duration of these responses was short and ranged from 4 to 8 months.These results suggest that fludarabine can be moderately effective in the treatment of MCL. Fludarabine appears to be far less effective than in chronic lymphocytic leukemia (CLL) and follicular non-Hodgkin's lymphoma (NHL). Therefore, fludarabine should be evaluated in association with other chemotherapeutic agents in MCL." @default.
• W2254608986 created "2016-06-24" @default.
• W2254608986 creator A5002553434 @default.
• W2254608986 creator A5005071483 @default.
• W2254608986 creator A5011831421 @default.
• W2254608986 creator A5038165030 @default.
• W2254608986 creator A5054694591 @default.
• W2254608986 creator A5062552733 @default.
• W2254608986 creator A5070508738 @default.
• W2254608986 creator A5083080728 @default.
• W2254608986 creator A5083914679 @default.
• W2254608986 creator A5089229030 @default.
• W2254608986 creator A5090298432 @default.
• W2254608986 date "1998-02-01" @default.
• W2254608986 modified "2023-09-25" @default.
• W2254608986 title "Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas." @default.
• W2254608986 cites W1009164044 @default.
• W2254608986 cites W101474840 @default.
• W2254608986 cites W1494274243 @default.
• W2254608986 cites W1536591710 @default.
• W2254608986 cites W1556385281 @default.
• W2254608986 cites W1785340630 @default.
• W2254608986 cites W1851503105 @default.
• W2254608986 cites W1901559524 @default.
• W2254608986 cites W1976340698 @default.
• W2254608986 cites W2032034804 @default.
• W2254608986 cites W2036873964 @default.
• W2254608986 cites W2095113053 @default.
• W2254608986 cites W2107202569 @default.
• W2254608986 cites W2122737399 @default.
• W2254608986 cites W2149529367 @default.
• W2254608986 cites W2159376479 @default.
• W2254608986 cites W2185675708 @default.
• W2254608986 cites W2210611916 @default.
• W2254608986 cites W2241314352 @default.
• W2254608986 cites W2259988458 @default.
• W2254608986 cites W2266889995 @default.
• W2254608986 cites W2272255210 @default.
• W2254608986 cites W2278012184 @default.
• W2254608986 cites W2309937882 @default.
• W2254608986 cites W2411708266 @default.
• W2254608986 cites W61258569 @default.
• W2254608986 doi "https://doi.org/10.1200/jco.1998.16.2.579" @default.
• W2254608986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9469344" @default.
• W2254608986 hasPublicationYear "1998" @default.
• W2254608986 type Work @default.
• W2254608986 sameAs 2254608986 @default.
• W2254608986 citedByCount "66" @default.
• W2254608986 countsByYear W22546089862012 @default.
• W2254608986 countsByYear W22546089862013 @default.
• W2254608986 countsByYear W22546089862015 @default.
• W2254608986 countsByYear W22546089862018 @default.
• W2254608986 countsByYear W22546089862021 @default.
• W2254608986 crossrefType "journal-article" @default.
• W2254608986 hasAuthorship W2254608986A5002553434 @default.
• W2254608986 hasAuthorship W2254608986A5005071483 @default.
• W2254608986 hasAuthorship W2254608986A5011831421 @default.
• W2254608986 hasAuthorship W2254608986A5038165030 @default.
• W2254608986 hasAuthorship W2254608986A5054694591 @default.
• W2254608986 hasAuthorship W2254608986A5062552733 @default.
• W2254608986 hasAuthorship W2254608986A5070508738 @default.
• W2254608986 hasAuthorship W2254608986A5083080728 @default.
• W2254608986 hasAuthorship W2254608986A5083914679 @default.
• W2254608986 hasAuthorship W2254608986A5089229030 @default.
• W2254608986 hasAuthorship W2254608986A5090298432 @default.
• W2254608986 hasConcept C126322002 @default.
• W2254608986 hasConcept C141071460 @default.
• W2254608986 hasConcept C143998085 @default.
• W2254608986 hasConcept C2776694085 @default.
• W2254608986 hasConcept C2776755627 @default.
• W2254608986 hasConcept C2777058707 @default.
• W2254608986 hasConcept C2777525834 @default.
• W2254608986 hasConcept C2777938653 @default.
• W2254608986 hasConcept C2778461978 @default.
• W2254608986 hasConcept C2779263901 @default.
• W2254608986 hasConcept C2779338263 @default.
• W2254608986 hasConcept C2781442060 @default.
• W2254608986 hasConcept C71924100 @default.
• W2254608986 hasConcept C90924648 @default.
• W2254608986 hasConceptScore W2254608986C126322002 @default.
• W2254608986 hasConceptScore W2254608986C141071460 @default.
• W2254608986 hasConceptScore W2254608986C143998085 @default.
• W2254608986 hasConceptScore W2254608986C2776694085 @default.
• W2254608986 hasConceptScore W2254608986C2776755627 @default.
• W2254608986 hasConceptScore W2254608986C2777058707 @default.
• W2254608986 hasConceptScore W2254608986C2777525834 @default.
• W2254608986 hasConceptScore W2254608986C2777938653 @default.
• W2254608986 hasConceptScore W2254608986C2778461978 @default.
• W2254608986 hasConceptScore W2254608986C2779263901 @default.
• W2254608986 hasConceptScore W2254608986C2779338263 @default.
• W2254608986 hasConceptScore W2254608986C2781442060 @default.
• W2254608986 hasConceptScore W2254608986C71924100 @default.
• W2254608986 hasConceptScore W2254608986C90924648 @default.
• W2254608986 hasIssue "2" @default.
• W2254608986 hasLocation W22546089861 @default.
• W2254608986 hasLocation W22546089862 @default.
• W2254608986 hasOpenAccess W2254608986 @default.
• W2254608986 hasPrimaryLocation W22546089861 @default.

• next